Eleven organisations from Germany, Switzerland and Great Britain have filed a joint opposition against a patent on genetically engineered chimpanzees granted to the US company Intrexon. Patent EP1456346 was granted by the European Patent Office (EPO) in February 2012. The animals will be manipulated with synthetic DNA originating from insects and are intended for use in pharmaceutical research. The joint opposition argues that this patent violates ethical provisions in patent law.
A briefing published today by public interest groups highlights how regulatory decisions on GM insects in Europe and around the world are being biased by corporate interests (1).
In a new backgrounder, Testbiotech shows that the European Food Safety Authority (EFSA) uses double standards in assessing scientific publications. According to an analysis presented today, the authority applies differing standards to assess risks of genetically engineered plants and EFSA´s findings appear to be influenced by assumptions.